Biomimetic nanoparticles for inflammation targeting

Kai Jin1, Zimiao Luo1,2, Bo Zhang1

  • 1School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, China.

Keywords:
Biomimetic nanoparticlesCAM, cellular adhesion moleculeCCL5, chemokine (C-C motif) ligand 5CD40L, cluster of differentiation 40 ligandCTC, circulating tumor cellCTL, cytotoxic T cell or CD8+ T cellCXCL4, chemokine (C-X-C motif) ligand 4CXCR1, chemokine (C-X-C motif) receptor 1Cell membraneCell membrane proteinsCy7, cyanine 7DC, dendritic cellDSPE-PEG, distearoyl Phosphoethanolamine-poly(ethylene glycol)GPIV, glycoprotein IVGPIX, glycoprotein IXGPIbα, glycoprotein IbαGPV, glycoprotein VGPVI, glycoprotein VIHUVEC, umbilical cord vascular endothelial cellIBD, inflammatory bowel diseaseICAM-1, intercellular cellular adhesion molecule-1IL, interleukinIgG, immunoglobulin GImmune cellsInflammation targetingLFA-1, lymphocyte function associated antigen-1LLV, leukocyte-like vectorLPS, lipopolysaccharideMHC, major histocompatibility complexMRI, magnetic resonance imagingMac-1, macrophage adhesion molecule-1Molecular imagingNM-NP, neutrophil membrane-coated nanoparticlePECAM-1, platelet-endothelial cellular adhesion molecule-1PLA-PEG, poly(lactic acid)-poly(ethylene glycol)PLGA, poly(lactic-co-glycolic acid)PNP, platelet membrane-cloaked nanoparticlePSGL-1, P-selectin glycoprotein ligand-1RA, rheumatoid arthritisRBC, red blood cellSLeX, sialyl lewis XSPIO, super paramagnetic iron oxideTGF-β, transforming growth factor βTNF-α, tumor necrosis factor-αTargeting ligandsTh cell, T-helper cell or CD4+ T cellVCAM-1, vascular cellular adhesion molecule-1VLA-4, very late antigen-4VWF, Von Willebrand factorapoE–/– mice, Apolipoprotein e knockout mice

Related Concept Videos

Inflammation01:38

Inflammation

Overview
62.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.9K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.5K
Target Cell Response to Hormones01:22

Target Cell Response to Hormones

Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
5.8K
Allergic Reactions02:06

Allergic Reactions

Overview
32.4K
DNA-only Transposons02:57

DNA-only Transposons

DNA-only transposons are called autonomous transposons since they code for the enzyme transposase that is required for the transposition mechanism. Insertion of transposons can alter gene functions in multiple ways. They can mutate the gene, alter gene expression by introducing a novel promoter or insulator sequence, introduce new splice sites, and change the mRNA transcripts produced, or remodel chromatin structure.
The donor site from where the transposon is excised is either degraded or...
17.5K